TrialTargeted oncology2025

Teclistamab Dosing in Responders: Modeling and Simulation Results from the MajesTEC-1 Study in Relapsed/Refractory Multiple Myeloma.

Yue Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.